M Colleoni
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
Colleoni M, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann R, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C, Litman H, Castiglione-Gertsch M, Sauerbrei W, Gelber R, Bonetti M, Coates A, Schumacher M, Bastert G, German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. British journal of cancer 2002; 86:1705-14.
05.06.2002Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
05.06.2002British journal of cancer 2002; 86:1705-14
Colleoni M, Collins J, Thürlimann Beat, Holmberg S B, Crivellari D, Beyerle C, Neumann R L A, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C-M, Litman H J, Castiglione-Gertsch M, Sauerbrei W, Gelber R D, Bonetti M, Coates A S, Schumacher M, Bastert G, German Breast Cancer Study Group
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Gelber S, International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9.
01.11.2001Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
01.11.2001Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9
Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S B, Thürlimann Beat, Collins J, Lindtner J, Rudenstam C M, Price K, Gelber R D, Castiglione-Gertsch M, Coates A S, Gelber S, International Breast Cancer Study Group
Identifying breast cancer patients at high risk for bone metastases
Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35.
01.12.2000Identifying breast cancer patients at high risk for bone metastases
01.12.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35
Colleoni M, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R D, Bonetti M, Thürlimann Beat, Price K N, Castiglione-Gertsch M, Coates A S, Rudenstam C M
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group
Colleoni M, Marini G, Veronesi A, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Bonetti M, Goldhirsch A. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:584-90.
01.02.2000Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group
01.02.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:584-90
Colleoni M, Marini G, Veronesi A, Holmberg S, Thürlimann Beat, Collins J, Lindtner J, Rudenstam C M, Price K, Gelber R D, Castiglione-Gertsch M, Coates A S, Bonetti M, Goldhirsch A
Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group
Colleoni M, Thürlimann B, Gelber R, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. European journal of cancer (Oxford, England : 1990) 1998; 34:1693-700.
01.10.1998Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group
01.10.1998European journal of cancer (Oxford, England : 1990) 1998; 34:1693-700
Colleoni M, Thürlimann Beat, Gelber R D, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C M